Benjamin Derman News Today

Physicians may need to rethink maintenance with lenalidomide (Revlimid and generics) for multiple myeloma.

Shortages, cost, and delays may reduce the effectiveness of CAR-T treatment and increase the risk of patient mortality in multiple myeloma.

The findings underscore the importance of ongoing research that will provide critical evidence supporting when MRD status can be used to intensify or de-escalate treatment.